A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Study acronym: REMERGE
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later Sep 30, 2026 → Dec 31, 2027
See other at-risk trials from Roche/Genentech

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 7 of 10 entries
    • Eligibility criteria expanded, about 13 words
    • Site details revised at 1 of 28 sites
  2. Primary and study completion pushed from Sep 30, 2026 to Dec 31, 2027v33
  3. 2 versions Re-verified since Jul 2, 2026, no change to tracked fieldsv31-v32
  4. Study Status, Contacts/Locations, Referencesv30
  5. 2 versions Re-verified since Apr 3, 2026, no change to tracked fieldsv28-v29
Show 26 earlier versionsHide 26 earlier versions
  1. Study sites: 26 to 28v27
  2. 4 versions Re-verified since Nov 14, 2025, no change to tracked fieldsv23-v26
  3. Site details revised at 1 of 26 sitesv22
  4. 2 versions Re-verified since Aug 5, 2025, no change to tracked fieldsv20-v21
  5. Study sites revised (26)v19
  6. 4 versions Re-verified since Mar 18, 2025, no change to tracked fieldsv15-v18
  7. Primary and study completion dates: Jan 28, 2027 to Sep 30, 2026v14
  8. Study sites: 25 to 26v13
  9. 4 versions Re-verified since Sep 24, 2024, no change to tracked fieldsv9-v12
  10. Study sites: 24 to 25v8
  11. Study sites: 18 to 24v7
  12. Study sites: 12 to 18v6
  13. Study sites: 9 to 12v5
  14. Study sites: 3 to 9v4
  15. Study sites: 1 to 3
    • Start date changed from estimate of Apr 15, 2024 to Apr 2, 2024
    v3
  16. Start date: Feb 12, 2024 to Apr 15, 2024v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
369 trials monitored
See 29 trials at risk
Breast Cancer
5,481 trials monitored
See 311 trials at risk
This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.
Trial Details
NCT Number NCT06274515
Lead Sponsor Hoffmann-La Roche
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 320 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov